Abstract
Standard treatments have shown dismal activity against pancreatic cancer (PC), due in part to the development of a dense stroma (desmoplasia). This perspective discusses the development of the di-2-pyridylketone thiosemicarbazones that overcomes bidirectional oncogenic signaling between PC cells and pancreatic stellate cells (PSCs), which is critical for desmoplasia development. This activity is induced by the up-regulation of the metastasis suppressor, N-myc downstream-regulated gene-1 (NDRG1), which inhibits oncogenic signaling via HGF, IGF-1 and Sonic Hedgehog pathway. More recent studies have deciphered additional pathways including those mediated by Wnt and tenascin C that are secreted by PSCs to activate β-catenin and YAP/TAZ signaling in PC cells. Suppression of bidirectional signaling between cell types presents a unique therapeutic opportunity.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74(11), 2913–2921 (2014).
- 2. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol. Ther. 155, 80–104 (2015).
- 3. The landscape of pancreatic cancer therapeutic resistance mechanisms. Int. J. Biol. Sci. 12(3), 273–282 (2016).
- 4. The effect of apoptotic activity, survivin, Ki-67, and P-glycoprotein expression on prognosis in pancreatic carcinoma. Pancreas. 30(4), 343–348 (2005).
- 5. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma. Anticancer Res. 27(4B), 2115–2120 (2007).
- 6. Stromal biology and therapy in pancreatic cancer. Gut. 60(6), 861–868 (2011).
- 7. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 68(7), 2085–2093 (2008).
- 8. . Microenvironment in determining chemo-resistance in pancreatic cancer: neighborhood matters. Pancreatology. 17(1), 7–12 (2017).
- 9. Kinome array profiling of patient-derived pancreatic ductal adenocarcinoma identifies differentially active protein tyrosine kinases. Int. J. Mol. Sci. 21(22), 8679 (2020).
- 10. Emerging kinase therapeutic targets in pancreatic ductal adenocarcinoma and pancreatic cancer desmoplasia. Int. J. Mol. Sci. 21(22), 8823 (2020).
- 11. Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol. Cancer Ther. 6(3), 1039–1045 (2007).
- 12. Redox cycling metals: pedaling their roles in metabolism and their use in the development of novel therapeutics. Biochim. Biophys. Acta, Mol. Cell Res. 1863(4), 727–748 (2016).
- 13. . Bioavailable copper modulates oxidative phosphorylation and growth of tumors. Proc. Natl. Acad. Sci. 110(48), 19507–19512 (2013).
- 14. Serum concentrations of selenium and copper in patients diagnosed with pancreatic cancer. Cancer Res. Treat. Official J. Korean Cancer Association. 48(3), 1056 (2016).
- 15. Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumor Biol. 33(5), 1695–1700 (2012).
- 16. Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. Oncol. Lett. 15(5), 8125–8133 (2018).
- 17. . The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 57(4), 547–583 (2005).
- 18. . Novel chelators for cancer treatment: where are we now? Antioxid. Redox Signal. 18(8), 973–1006 (2013).
- 19. . The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood. 86, 4295–4306 (1995).
- 20. . Novel ‘hybrid’ iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood. 100(2), 666–676 (2002).
- 21. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J. Med. Chem. 49(22), 6510–6521 (2006).
- 22. . A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. 103(40), 14901–14906 (2006).
- 23. . Novel di-2-pyridyl–derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood. 104(5), 1450–1458 (2004).
- 24. . Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol. Pharmacol. 80(4), 598–609 (2011).
- 25. N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol. Med. 4(2), 93–108 (2012).
- 26. . Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Br. J. Pharmacol. 165(1), 148–166 (2012).
- 27. Breaking the cycle: Targeting of NDRG1 to inhibit bi-directional oncogenic cross-talk between pancreatic cancer and stroma. FASEB J. 35(2), e21347 (2021). •• This article is of considerable interest as it provides the evidence regarding the inhibition of bidirectional signaling between pancreatic cancer cells and pancreatic stellate cells.
- 28. The metastasis suppressor, N-MYC downstream-regulated gene-1 (NDRG1), down-regulates the ErbB family of receptors to inhibit downstream oncogenic signaling pathways. J. Biol. Chem. 291(3), 1029–1052 (2016).
- 29. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J. Med. Chem. 55(16), 7230–7244 (2012).
- 30. The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms. J. Hematol. Oncol. 9(1), 1–16 (2016).
- 31. Unique targeting of androgen-dependent and-independent AR signaling in prostate cancer to overcome androgen resistance. FASEB J. 34(9), 11511–11528 (2020).
- 32. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget. 6(40), 42411 (2015).
- 33. The renaissance of polypharmacology in the development of anti-cancer therapeutics: inhibition of the ‘triad of death’ in cancer by Di-2-pyridylketone thiosemicarbazones. Pharmacol. Res. 100, 255–260 (2015).
- 34. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res. 71(17), 5871–5880 (2011).
- 35. Zinc (II)–thiosemicarbazone complexes are localized to the lysosomal compartment where they transmetallate with copper ions to induce cytotoxicity. J. Med. Chem. 59(10), 4965–4984 (2016).
- 36. . Repurposing cationic amphiphilic drugs and derivatives to engage lysosomal cell death in cancer treatment. Front. Oncol. 2837 (2020).
- 37. The growing evidence for targeting P-glycoprotein in lysosomes to overcome resistance. Future Med. Chem. 12(6), 473–477 (2020).
- 38. . The lysosome: from waste bag to potential therapeutic target. J. Mol. Cell Biol. 5(4), 214–226 (2013).
- 39. Di-2-pyridylketone 4, 4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp). J. Biol. Chem. 290(15), 9588–9603 (2015).
- 40. . A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC. Cell Death Dis. 7(12), e2510–e2510 (2016).
- 41. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J. Biol. Chem. 288(44), 31761–31771 (2013).
- 42. Structure–activity relationships of di-2-pyridylketone, 2-benzoylpyridine, and 2-acetylpyridine thiosemicarbazones for overcoming Pgp-mediated drug resistance. J. Med. Chem. 59(18), 8601–8620 (2016).
- 43. . Glucose modulation induces lysosome formation and increases lysosomotropic drug sequestration via the P-glycoprotein drug transporter. J. Biol. Chem. 291(8), 3796–3820 (2016).
- 44. . Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood. 104(9), 2967–2975 (2004).
- 45. N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of κB kinase β expression. Cancer Res. 69(12), 4983–4991 (2009).
- 46. Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res. 66(12), 6233–6242 (2006).
- 47. The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid. Redox Signal. 18(8), 874–887 (2013).
- 48. The metastasis suppressor, NDRG1, attenuates oncogenic TGF-β and NF-κB signaling to enhance membrane E-cadherin expression in pancreatic cancer cells. Carcinogenesis. 40(6), 805–818 (2019).
- 49. The iron chelators Dp44mT and DFO inhibit TGF-beta-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J. Biol. Chem. 287(21), 17016–17028 (2012).
- 50. The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of β-catenin through mechanisms involving FRAT1 and PAK4. J. Cell Sci. 127(14), 3116–3130 (2014).
- 51. The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. Oncotarget. 6(11), 8851 (2015).
- 52. Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway. Mol. Pharmacol. 83(2), 454–469 (2013).
- 53. Targeting the metastasis suppressor, N-Myc downstream regulated gene-1, with novel di-2-pyridylketone thiosemicarbazones: Suppression of tumor cell migration and cell-collagen adhesion by inhibiting focal adhesion kinase/paxillin signaling. Mol. Pharmacol. 89(5), 521–540 (2016).
- 54. Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding. J. Biol. Chem. 295(2), 481–503 (2020).
- 55. . The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6. J. Biol. Chem. 294(11), 4045–4064 (2019).
- 56. . Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat. Rev. Cancer. 7(5), 357–369 (2007).
- 57. How to design multi-target drugs: target search options in cellular networks. Expert Opin. Drug Discov. 2(6), 799–808 (2007).
- 58. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 467(7319), 1109–1113 (2010).
- 59. Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures. J. Med. Chem. 48(4), 1079–1087 (2005).
- 60. Pancreatic cancer. Nat. Rev. Dis. Primers. 2(1), 1–22 (2016).
- 61. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas. 29(3), 179–187 (2004).
- 62. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. Br. J. Cancer. 114(3), 269–280 (2016).
- 63. Heterogeneous stromal signaling within the tumor microenvironment controls the metastasis of pancreatic cancer. Cancer Res. 77(1), 41–52 (2017).
- 64. Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation. Cell. 165(4), 910–920 (2016).
- 65. . Deciphering the role of hedgehog signaling in pancreatic cancer. J. Biomed. Res. 30(5), 353 (2016).
- 66. . Characterization of sonic hedgehog as a novel NF-κB target gene that promotes NF-κB-mediated apoptosis resistance and tumor growth in vivo. FASEB J. 23(1), 21–33 (2009).
- 67. Nuclear factor-κB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Res. 66(14), 7041–7049 (2006).
- 68. Wnt signaling stimulates transcriptional outcome of the Hedgehog pathway by stabilizing GLI1 mRNA. Cancer Res. 69(22), 8572–8578 (2009).
- 69. . Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int. J. Mol. Sci. 18(7), 1338 (2017).
- 70. . Chemotherapy and tumor microenvironment of pancreatic cancer. Cancer Cell Int. 17(1), 1–17 (2017).
- 71. Targeting Wnt/Tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation of the metastasis suppressor NDRG1. J. Biol. Chem. 101608 (2022). • Provides additional molecular evidence regarding the ability of NDRG1 to inhibit bidirectional crosstalk between pancreatic cancer cells and pancreatic stellate cells.
- 72. Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer. Oncotarget. 8(44), 76722 (2017).
- 73. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am. J. Pathol. 177(5), 2585–2596 (2010).
- 74. . Pancreatic stellate cells: a starring role in normal and diseased pancreas. Front. Physiol. 3, 344 (2012).
- 75. α-Smooth muscle actin expressing stroma promotes an aggressive tumor biology in pancreatic ductal adenocarcinoma. Pancreas. 39(8), 1254–1262 (2010).